A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies
Status:
Recruiting
Trial end date:
2024-12-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the feasibility of subcutaneous (SC) administration of
amivantamab based on safety and pharmacokinetics and determine a dose, dose regimen and
formulation for amivantamab SC delivery.